---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113404"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T17:54:15.091565+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kintara stockholders approve TuHURA merger; FY2024 net loss $8.32M

## Summary
- Stockholders approved merger with TuHURA on Oct 4, 2024; closing expected mid-October 2024.
- Cash and equivalents $4.9M as of June 30, 2024.
- FY2024 net loss $8.3M ($0.32 loss per share), improved from $14.6M ($9.27 loss) in FY2023.
- REM-001 study dosed 4 patients; $2.0M NIH grant covers most costs; R&D expenses fell 71%.

## SEC filing metadata
- accession: 0000950170-24-113404
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024113404/0000950170-24-113404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024113404/ktra-20241007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113404
- JSON: https://secwatch.observer/filing/0000950170-24-113404.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.